6/7/2010

Biotech firm Ascenta Therapeutics agreed to license its cancer drug candidates, including MI-773 and MI-519-64, to Sanofi-Aventis. The deal entitles Ascenta to get as much as $398 million from Sanofi.

Full Story:
Reuters

Related Summaries